^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | bintrafusp alfa (M7824) (PD-L1 inhibitor, TGFβ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Retrospective clinical analysis of circulating tumor DNA (ctDNA)–based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response in phase 3 trial of bintrafusp alfa vs. pembrolizumab treatment of non-small cell lung cancer (NSCLC).
Published date:
05/25/2023
Excerpt:
ctDNA was collected at baseline and day 42 after treatment with bintrafusp alfa (Q2W, 1200mg) or pembrolizumab (Q3W, 200mg)....In the bintrafusp alpha arm, PFS was significantly longer in patients with bTMB-H (median 8.3 months vs 2.7 months, p = 0.00086).
DOI:
10.1200/JCO.2023.41.16_suppl.9098
Trial ID:
Test:
